United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch “Braving NeuroBLASToma” in Honor of Childhood Cancer Awareness Month
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, NC, Aug. 25, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is joining forces with former NFL player Devon Still and his daughter Leah, a survivor of high-level neuroblastoma. risk, to launch the “Braving NeuroBLASToma” educational initiative that sheds light on the rare cancer that affects immature nerve cells called neuroblasts.iv Neuroblastoma often develops in infants and children under the age of five, but the average age at which it is diagnosed is between one and two years old.
About 800 children are diagnosed with neuroblastoma each year, accounting for seven to ten percent of all childhood cancers in the United States. v,vi At the time of diagnosis, nearly 70 percent of children will have advanced or metastatic neuroblastoma, with only half of these patients achieving remission.vii,viii Neuroblastoma can begin to form in several places, including near the abdomen, spine, chest, or adrenal glands.ix
“When I first learned that Leah had high-risk neuroblastoma, the feeling of fear and helplessness was so overwhelming that I struggled to know where to start,” Devon Still said. “Over the years, so many in the pediatric cancer community have shown us how much they care about every step, from making the tough decisions to ensuring Leah’s comfort during treatment. By partnering with United Therapeutics, we can enhance our personal experiences in defying neuroblastoma and lend others the support we have so generously received over the years.”
Proud NeuroBLASToma Features:
A family-friendly toolkit with a resource-packed website, including an extensive library of information and resources, such as physician questions, navigating clinical trials, treatment insights, and advice for healthcare providers. A series of four beautifully illustrated books, including the latest issue of Zara Takes Off – inspiring hope and encouragement as families transition into life after treatment. The new release includes a personal foreword written by Leah, sharing details of her personal journey. Each book highlights different stages of the journey with high-risk neuroblastoma, starting with The Big Adventures of Little Skivolo helping families understand diagnosis and treatment, The Next Big Adventure of Little Skivolo specifically targeting the antibody therapy phase of treatment , Little Skivolo’s Big Book of Fun, an activity book to entertain children and families during hospital stays and culminates in Zara Takes Off.
“United Therapeutics has partnered with leading pediatric neuroblastoma researchers for many years, including the Children’s Oncology Group, supported by the National Cancer Institute, to bring hope to thousands of families battling this deadly childhood cancer,” said Karren Jackson. , head of the oncology program. at United Therapeutics. “We are extremely proud to partner with Devon Still and his daughter Leah to highlight what courage, resilience and support from loved ones can do for children and their families affected by neuroblastoma.”
As treatment comes to an end, families can move from treatment mode to more familiar routines, while the health care team continues to monitor the child’s recovery. But neuroblastoma’s journey doesn’t stop there, patients will continue to see their oncology team on a routine basis to check for long-term side effects and to make sure the cancer has not returned. This part of the journey requires constant vigilance, support and encouragement.
“Treating a child with high-risk neuroblastoma challenges both patients and caregivers, with each family enduring unique and evolving medical needs,” said Rochelle Bagatell, MD, a pediatric oncologist, Children’s Hospital of Philadelphia, and chair of the Neuroblastoma Committee for the Study of Neuroblastoma. pediatric oncology group. “As a caregiver, I encourage families to use the resources available to them so that we can work together to ensure that every child receives the best possible care and support.”
For more information, visit BravingNeuroBLASToma.com, a comprehensive resource for every step of the patient journey.
Neuroblastoma is the most common cancer in infants under one year of age, but is considered a rare cancer.i Each year, approximately 800 children are diagnosed with neuroblastoma, representing seven to ten percent of all cancers in children in the United States.v, vi This solid tumor cancer begins in immature nerve cells called neuroblasts and often develops in infants and children under the age of five, but the average age of diagnosis is between one and two years.iv Neuroblastoma can form anywhere along the sympathetic nerve chain and is commonly seen in the abdomen, spine, chest, or adrenal glands.ix At the time of diagnosis, nearly 70 percent of children will have advanced or metastatic neuroblastoma.vii Despite advances in research and approval of treatments for neuroblastoma, there remains a significant unmet need for high-risk neuroblastoma patients nts. For children with high-risk childhood neuroblastoma, even when treated and remission is achieved, about 50-60% will relapse (the disease returns) and about 10% of children with high-risk childhood neuroblastoma will not respond prior to chemotherapy. refractory neuroblastoma.x There is currently no cure for recurrent high-risk neuroblastoma.xi
United Therapeutics: enabling inspiration
United Therapeutics Corporation focuses on the power of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental qualities, namely our obsession for quality and innovation, the strength of our brands, our entrepreneurial culture and our leadership in bioinformatics. We also believe that our determination to be responsible citizens – positively impacting patients, the environment and society – will support our long-term success.
Through our wholly owned subsidiary, Lung Biotechnology PBC, we focus on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that slow the need for such organs or increase the supply. Lung Biotechnology is the first subsidiary of a public biotechnology or pharmaceutical company.
Visit unither.com for more information.
Statements in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include our ability to create value and maintain our long-term success, as well as our efforts to develop technologies that slow down the need for transplantable organs or increase the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, as described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from those anticipated. Accordingly, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of August 25, 2021 and assume no obligation to update or revise the information in this press release, whether as a result of new information, future events or any other reason.
i American Cancer Society. Key Statistics. https://www.cancer.org/cancer/neuroblastoma/about/key-statistics.html
ii Children’s Neuroblastoma Cancer Foundation. Frequently Asked Questions. https://www.cncfhope.org/about-cncf/faqs/
iii American Cancer Society. Types of cancer that develop in children. https://www.cancer.org/cancer/cancer-in-children/types-of-childhood-cancers.html
v Cancer.net. Neuroblastoma childhood: statistics. https://www.cancer.net/cancer-types/neuroblastoma-childhood/statistics#:~:text=Each%20year%2C%20about%20800%20children,1%20and%202%20years%20old.
vi St. Jude Children’s Research Hospital. neuroblastoma. https://together.stjude.org/en-us/about-pediatric-cancer/types/neuroblastoma.html
vii Summaries of PDQ cancer information. Neuroblastoma treatment. https://www.ncbi.nlm.nih.gov/books/NBK65747/
viii Dana Farber Cancer Institute. Neuroblastoma in children. https://www.dana-farber.org/childhood-neuroblastoma/
ix Cancer. Net. Neuroblastoma childhood: introduction. https://www.cancer.net/cancer-types/neuroblastoma-childhood/introduction
View original content to download multimedia: https://www.prnewswire.com/news-releases/united-therapeutics-partners-with-former-nfl-player-devon-still-and-his-daughter-leah-to- launch-braving-neuroblastoma-in-honour-child-cancer-awareness-month-301362240.html
SOURCE United Therapeutics Corporation